Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $50.1 million.

  • Sangamo Therapeutics' Total Current Liabilities rose 1613.49% to $50.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 1613.49%. This contributed to the annual value of $45.8 million for FY2024, which is 403.51% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Total Current Liabilities stood at $50.1 million for Q3 2025, which was up 1613.49% from $47.7 million recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Total Current Liabilities ranged from a high of $136.9 million in Q2 2021 and a low of $39.0 million during Q2 2024
  • Over the past 5 years, Sangamo Therapeutics' median Total Current Liabilities value was $53.8 million (recorded in 2023), while the average stood at $80.3 million.
  • In the last 5 years, Sangamo Therapeutics' Total Current Liabilities surged by 11403.21% in 2021 and then crashed by 6037.79% in 2023.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Total Current Liabilities stood at $127.9 million in 2021, then dropped by 12.65% to $111.7 million in 2022, then plummeted by 57.27% to $47.7 million in 2023, then decreased by 4.04% to $45.8 million in 2024, then grew by 9.43% to $50.1 million in 2025.
  • Its Total Current Liabilities was $50.1 million in Q3 2025, compared to $47.7 million in Q2 2025 and $49.6 million in Q1 2025.